Straight answers to the questions every founder asks.

Yes. U.S. securities law provides established pathways for non-U.S. businesses — typically through a U.S. issuer or holding entity for Regulation A+ offerings, or directly as a foreign private issuer under Form F-1. Hundreds of international companies trade in U.S. markets. The question is rarely whether a route exists; it is whether the company is prepared for it.

Indicatively, 9 to 18 months from a standing start — driven mostly by audit readiness and corporate structuring, then by regulatory review cycles. Companies with clean structures and recent audits move faster; companies needing multi-year audit reconstruction move slower. We give a company-specific timeline after discovery, and we do not guarantee timelines — no honest adviser can.

Costs vary widely with pathway, audit complexity, and company readiness — spanning legal, audit, filing agents, transfer agents, and advisory fees. What we commit to is structure: milestone-based phases with costs understood before each phase begins, so you are never surprised. A realistic budget discussion is part of every discovery conversation.

Size matters less than quality and trajectory. Regulation A+ and OTC pathways were designed for growth-stage companies, not giants. What markets require is real revenue or a credible path to it, auditable financials, and a management team investors can trust. Some excellent companies should still wait — and we will say so.

A traditional IPO uses a full registration statement (S-1 or F-1), typically involves underwriters, has no raise ceiling, and supports immediate exchange listing. Regulation A+ is an exemption with streamlined disclosure, a $75 million annual ceiling at Tier 2, general solicitation freedom, and lighter ongoing reporting. Many companies use Reg A+ as the public foundation and pursue exchange uplisting later. See our Regulation A+ guide.

National exchanges have quantitative listing standards — share price, market value, shareholders' equity, and governance requirements. Many international companies begin with OTC Markets quotation, build a track record, and uplist when they meet exchange standards. We design programs with that progression in mind where it fits the company's trajectory.

We provide strategic advisory and coordination: readiness assessment, structuring guidance, document preparation support, and management of the professional ecosystem (securities counsel, PCAOB auditors, transfer agents, EDGAR agents, market makers, IR). We are not a broker-dealer, underwriter, law firm, audit firm, or custodian of investor funds — those regulated functions are performed by licensed providers we coordinate.

No — and you should walk away from anyone who does. Regulatory qualification depends on review outcomes; capital raising depends on markets and investors. What we control is preparation quality, process discipline, and honest sequencing, which together determine most of the difference between companies that complete the journey and those that stall.

In milestone-based phases — typically discovery, structuring and preparation, filings through qualification, and market debut — each with defined deliverables and costs agreed in advance. You always know where the program stands and what comes next.

Excellent professionals optimize their own workstream; someone must own the whole. Sequencing audits against filings, keeping counsel, auditors, and agents on one timeline, and translating between an emerging-market company and U.S. process expectations is a full-time discipline. That coordination — plus candid strategic judgment — is what we add. We work with your existing advisers gladly.

With a confidential discovery conversation: your business, your objectives, your current structure and financials. From that we provide a candid readiness view and, where appropriate, a proposed program. Contact us here.